MCID: FML037
MIFTS: 50

Female Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Female Breast Cancer

MalaCards integrated aliases for Female Breast Cancer:

Name: Female Breast Cancer 12 14
Female Breast Carcinoma 12 14 69
Malignant Neoplasm of Female Breast 69
Mammary Carcinoma of Female Breast 12
Carcinoma of Female Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050671 DOID:7843
NCIt 47 C2918
UMLS 69 C0007104

Summaries for Female Breast Cancer

Disease Ontology : 12 A breast carcinoma that is manifested in the female breast.

MalaCards based summary : Female Breast Cancer, also known as female breast carcinoma, is related to blastema predominant kidney wilms' tumor and autoimmune disease of blood. An important gene associated with Female Breast Cancer is PGR (Progesterone Receptor), and among its related pathways/superpathways are DNA Double-Strand Break Repair and Pathways in cancer. The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and growth/size/body region

Related Diseases for Female Breast Cancer

Diseases related to Female Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
id Related Disease Score Top Affiliating Genes
1 blastema predominant kidney wilms' tumor 10.8 PGR TP53
2 autoimmune disease of blood 10.8 BRCA2 PGR
3 selective immunoglobulin deficiency disease 10.8 BRCA2 PGR
4 gastritis 10.8 ERBB2 PGR
5 bartholin's gland benign neoplasm 10.8 ESR1 PGR
6 breast myoepithelial neoplasm 10.8 PGR TP53
7 gallbladder leiomyoma 10.8 ESR1 PGR
8 leiomyoma cutis 10.8 PGR TP53
9 cutaneous lupus erythematosus 10.8 BRCA2 ERBB2
10 prostatic acinar adenocarcinoma 10.8 PGR TP53
11 fallopian tube benign neoplasm 10.8 ESR1 PGR
12 intraductal breast myoepitheliosis 10.8 PGR TP53
13 skin sarcoma 10.8 ERBB2 PGR
14 paranasal sinus disease 10.8 ESR1 PGR
15 thai symphalangism syndrome 10.8 BRCA2 TP53
16 dartoic leiomyoma 10.8 ESR1 PGR
17 her2-receptor negative breast cancer 10.8 ERBB2 PGR
18 fallopian tube clear cell adenocarcinoma 10.8 ESR1 TP53
19 urinary bladder inverted papilloma 10.7 ESR1 PGR
20 congenital disorder of glycosylation, type if 10.7 ERBB2 TP53
21 deafness, autosomal dominant 8/12 10.7 ESR1 PGR
22 superficial basal cell carcinoma 10.7 ESR1 PGR
23 baraitser-winter cerebrofrontofacial syndrome 10.7 BRCA2 PALB2
24 animal phobia 10.7 ERBB2 TP53
25 pineal region meningioma 10.7 ESR1 PGR
26 bladder colloid adenocarcinoma 10.7 ESR1 PGR
27 endophthalmitis 10.7 ESR1 PGR
28 kallmann syndrome 10.7 ERBB2 PGR
29 penis squamous cell carcinoma 10.7 ERBB2 PGR
30 breast myoepitheliosis 10.7 ESR1 TP53
31 nerve fibre bundle defect 10.7 ERBB2 ESR1
32 central nervous system germ cell tumor 10.7 PGR TP53
33 cystic kidney disease 10.6 ERBB2 TP53
34 cutaneous mucoepidermoid carcinoma 10.6 ESR1 PGR
35 pulmonary embolism and infarction 10.6 AR TP53
36 holoprosencephaly 6 10.6 ESR1 PGR
37 breast pericanalicular fibroadenoma 10.6 BRCA2 PGR TP53
38 acute thyroiditis 10.6 ESR1 PGR
39 bowman's membrane folds or rupture 10.6 AR PGR
40 breast cancer 10.6
41 orbital lymphoma 10.6 ERBB2 TP53
42 central nervous system organ benign neoplasm 10.6 ESR1 PGR TP53
43 lung adenoma 10.6 ESR1 PGR TP53
44 colon neuroendocrine neoplasm 10.6 ERBB2 PGR TP53
45 endocervicitis 10.6 BRCA2 ERBB2 TP53
46 breast fibrosarcoma 10.6 ERBB2 PGR TP53
47 otitis externa 10.6 ERBB2 PGR TP53
48 bacteremia 10.6 BRCA2 PALB2
49 intestinal perforation 10.6 ESR1 PGR TP53
50 extracranial neuroblastoma 10.6 BRCA2 ERBB2 TP53

Comorbidity relations with Female Breast Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Breast Fibroadenosis
Deficiency Anemia Fat Necrosis of Breast
Hypertension, Essential Hypothyroidism
Mastitis Microglandular Adenosis
Neutropenia

Graphical network of the top 20 diseases related to Female Breast Cancer:



Diseases related to Female Breast Cancer

Symptoms & Phenotypes for Female Breast Cancer

GenomeRNAi Phenotypes related to Female Breast Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 ATM BRCA2 ERCC4 PALB2 TOP2A TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 BRCA2 ERCC4 PALB2 TOP2A TP53 ATM
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 ATM BRCA2 ERCC4 PALB2 TOP2A TP53

MGI Mouse Phenotypes related to Female Breast Cancer:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.2 PHB TP53 ATM BRCA2 CYP1A1 ERBB2
2 cellular MP:0005384 10.18 AR ATM BRCA2 ERBB2 ERCC4 ESR1
3 homeostasis/metabolism MP:0005376 10.17 TOX3 TP53 AR ATM BRCA2 CYP1A1
4 cardiovascular system MP:0005385 10.14 AR ATM CYP1A1 ERBB2 ESR1 PALB2
5 endocrine/exocrine gland MP:0005379 10.13 AR ATM BRCA2 CYP1A1 ERBB2 ESR1
6 embryo MP:0005380 10.1 AR ATM BRCA2 ERBB2 ESR1 PALB2
7 integument MP:0010771 10.1 AR ATM BRCA2 ERBB2 ERCC5 ESR1
8 mortality/aging MP:0010768 10.07 PGR PHB TOX3 TP53 AR ATM
9 digestive/alimentary MP:0005381 9.99 AR BRCA2 ERBB2 ERCC5 ESR1 TP53
10 limbs/digits/tail MP:0005371 9.91 AR BRCA2 ERBB2 ESR1 PALB2 PGR
11 liver/biliary system MP:0005370 9.8 ERCC4 ERCC5 ESR1 TP53 AR CYP1A1
12 neoplasm MP:0002006 9.76 AR ATM BRCA2 ERBB2 ESR1 PALB2
13 normal MP:0002873 9.5 AR BRCA2 CYP1A1 ERBB2 ESR1 PGR
14 reproductive system MP:0005389 9.23 AR ATM BRCA2 ERBB2 ESR1 PGR

Drugs & Therapeutics for Female Breast Cancer

Drugs for Female Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 742)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
4
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
6
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
7
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
8
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120511-73-1 2187
9
Diazepam Approved, Illicit, Vet_approved Phase 4 439-14-5 3016
10
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
11
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10540-29-1 2733526
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
14
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757
15
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3 71-58-9
16
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-83-0 5994
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
18
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129453-61-8 104741 17756771
19
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 216974-75-3
20
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
22
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
23
Benzocaine Approved Phase 4,Phase 2 1994-09-7, 94-09-7 2337
24
Palbociclib Approved Phase 4,Phase 3,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
25
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
26
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 180288-69-1 9903
27
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
28
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
29
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
30
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
31
Etidronic acid Approved Phase 4,Phase 3 7414-83-7, 2809-21-4 3305
32
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
33
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
34
Lactulose Approved Phase 4 4618-18-2 11333
35
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
36
Ropivacaine Approved Phase 4,Phase 2,Phase 3 84057-95-4 71273 175805
37
Bazedoxifene Approved, Investigational Phase 4,Phase 3,Phase 2 198481-32-2
38
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
39
Fosaprepitant Approved Phase 4 172673-20-0 219090
40
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
41
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
42
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 5595
43
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
44
Sulbactam Approved Phase 4 68373-14-8
45
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345
46
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1 59467-70-8 4192
47
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2 2078-54-8 4943
48
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 2180-92-9, 38396-39-3 2474
49
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
50
Sevoflurane Approved, Vet_approved Phase 4,Phase 2 28523-86-6 5206

Interventional clinical trials:

(show top 50) (show all 2887)

id Name Status NCT ID Phase Drugs
1 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4 liposomal doxorubicin;epirubicin
2 Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women Unknown status NCT01069211 Phase 4
3 Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer Unknown status NCT00352872 Phase 4
4 National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations Unknown status NCT00413491 Phase 4
5 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
6 Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene Unknown status NCT01072318 Phase 4 Letrozole
7 Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors Unknown status NCT00111241 Phase 4 aromatase inhibitors (letrozole, anastrozole)
8 The MONET - Study: MR Mammography of Nonpalpable Breast Tumors Unknown status NCT00302120 Phase 4
9 Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer Unknown status NCT00484614 Phase 4
10 Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer Unknown status NCT01612871 Phase 4 Tamoxifen, Letrozole , Anastrozole, Exemestane
11 WHAT (Women, Hot-flashes, Activity, Trial) - Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women Unknown status NCT01282320 Phase 4
12 Aromatase Inhibitor Clinical Trial Unknown status NCT00228956 Phase 4 pharmacodynamic analysis
13 Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer Unknown status NCT02158299 Phase 4 Avitene;Sapylin
14 Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma Unknown status NCT00307606 Phase 4 Solu-medrol 125 mg
15 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
16 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
17 Promoting Breast Cancer Screening in Non-adherent Women Completed NCT01332032 Phase 4
18 Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment Completed NCT01859936 Phase 4
19 A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer Completed NCT00544986 Phase 4 Anastrozole
20 Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer Completed NCT00014638 Phase 4 letrozole
21 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Completed NCT01231659 Phase 4 Everolimus + Letrozole
22 Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer Completed NCT00082277 Phase 4 Anastrozole;Risedronate Sodium
23 Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Completed NCT00237133 Phase 4 Letrozole
24 Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole Completed NCT00237224 Phase 4 Letrozole
25 A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer Completed NCT00121836 Phase 4 Capecitabine;Bevacizumab
26 Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer Completed NCT00493350 Phase 4
27 Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy Completed NCT00485953 Phase 4 risedronate
28 Wellbutrin XL, Major Depressive Disorder and Breast Cancer Completed NCT00234195 Phase 4 bupropion extended release (Wellbutrin XL)
29 Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00022386 Phase 4
30 A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer Completed NCT00649090 Phase 4 exemestane
31 Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer Completed NCT00688909 Phase 4 letrozole
32 Accelerated Radiotherapy Outcomes in Women Completed NCT00156130 Phase 4
33 Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery Completed NCT00785382 Phase 4 Placebo;Pregabalin 150 mg
34 Arthralgia During Anastrozole Therapy for Breast Cancer Completed NCT00323479 Phase 4 Anastrozole
35 Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk Completed NCT00839696 Phase 4
36 Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer Completed NCT00160901 Phase 4 two complex naturopathic add-on therapies, leaflet 5-a-day
37 Chlorhydrate of Ropivacaine and Breast Cancer Surgery Completed NCT00370240 Phase 4 Chlorhydrate de Ropivacaine
38 Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density Completed NCT00418236 Phase 4
39 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
40 Post Market Study Using the Xoft Axxent System Completed NCT01017549 Phase 4
41 A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer Completed NCT01094184 Phase 4 bevacizumab [Avastin]
42 Randomized Trial of Follow-up Strategies in Breast Cancer Completed NCT00156039 Phase 4
43 Life Quality and Mental State in Patients With Breast Cancer Completed NCT01458457 Phase 4
44 Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients Completed NCT00128778 Phase 4 Pegylated liposomal doxorubicin (Caelyx)
45 Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients Completed NCT01298193 Phase 4 Aprepitant
46 Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer Completed NCT01199432 Phase 4 5-FU(intravenous infusion)+epirubicin+cyclophosphamide;5-FU(intravenous bolus)+epirubicin+cyclophosphamide;epirubicin+cyclophosphamide
47 Symptom Management After Breast Cancer Surgery Completed NCT00686127 Phase 4 Lidoderm patch;Placebo patch
48 The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients. Completed NCT00356148 Phase 4 Ampicillin/Sulbactam
49 Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study Completed NCT00176046 Phase 4 viscum album pini;viscum album pini
50 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women Completed NCT01048606 Phase 4

Search NIH Clinical Center for Female Breast Cancer

Genetic Tests for Female Breast Cancer

Anatomical Context for Female Breast Cancer

MalaCards organs/tissues related to Female Breast Cancer:

39
Breast, Bone, Lymph Node, Testes, Brain, Skin, Lung

Publications for Female Breast Cancer

Articles related to Female Breast Cancer:

(show top 50) (show all 111)
id Title Authors Year
1
BRIP1/FANCJ Mutation Analysis in a Family with History of Male and Female Breast Cancer in India. ( 28382101 )
2017
2
Marital adjustment in the context of female breast cancer: A systematic review. ( 28342270 )
2017
3
Association between SNPs in Long Non-coding RNAs and the Risk of Female Breast Cancer in a Chinese Population. ( 28607590 )
2017
4
Geographic variations in female breast cancer incidence in relation to ambient air emissions of polycyclic aromatic hydrocarbons. ( 28616736 )
2017
5
Perceptions of Arab men regarding female breast cancer screening examinations-Findings from a Middle East study. ( 28732040 )
2017
6
Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens. ( 28639031 )
2017
7
Descriptive Epidemiology of Female Breast Cancer in Delhi, India ( 28545200 )
2017
8
Predictors of quality of life in Czech female breast cancer survivors following treatment with special interest to coping strategies. ( 28840734 )
2017
9
No genetic relationship between TLR2 rs4696480, rs3804100, and rs3804099 gene polymorphisms and female breast cancer in Saudi populations. ( 28490891 )
2017
10
No Evaluation of Serum P53 Levels in Iraqi Female Breast Cancer Patients ( 28952299 )
2017
11
Trends in Female Breast Cancer by Age Group in the Chiang Mai Population ( 28612595 )
2017
12
Predictors of distress in female breast cancer survivors: a systematic review. ( 28553684 )
2017
13
Model-based Recursive Partitioning for Survival of Iranian Female Breast Cancer Patients: Comparing with Parametric Survival Models. ( 28451527 )
2017
14
Familial associations of female breast cancer with other cancers. ( 28801919 )
2017
15
Metastasis and its Related Factors in Female Breast Cancer Patients in Kerman, Iran ( 28669169 )
2017
16
Clinical outcomes of female breast cancer according to BRCA mutation status. ( 28601786 )
2017
17
Exploring neighborhood inequality in female breast cancer incidence in Tehran using Bayesian spatial models and a spatial scan statistic. ( 28774168 )
2017
18
Disparities in Female Breast Cancer Stage at Diagnosis in New Jersey: A Spatial-Temporal Analysis. ( 28430705 )
2017
19
Depressive symptoms during adverse economic and political circumstances: A comparative study on Greek female breast cancer patients receiving chemotherapy treatment. ( 28398649 )
2017
20
Physical symptoms and working performance in female breast cancer survivors: a systematic review. ( 28325132 )
2017
21
Geographical and Temporal Variations in Female Breast Cancer Mortality in the Municipalities of Andalusia (Southern Spain). ( 27879690 )
2016
22
Optical Screening of Female Breast Cancer from Whole Blood Using Raman Spectroscopy. ( 27634888 )
2016
23
Mutations in Human Interferon I+2b Gene and Potential as Risk Factor Associated with Female Breast Cancer. ( 27403569 )
2016
24
Type 2 Diabetes Mellitus as a Risk Factor for Female Breast Cancer in the Population of Northern Pakistan. ( 27509959 )
2016
25
Atrial Fibrillation is Associated With Morphine Treatment in Female Breast Cancer Patients: A Retrospective Population-Based Time-Dependent Cohort Study. ( 26986153 )
2016
26
Utilization of an Anti-Gravity Treadmill in a Physical Activity Program with Female Breast Cancer Survivors: A Pilot Study. ( 27293508 )
2016
27
Effect of a multidiscipline mentor-based program, Be Resilient to Breast Cancer (BRBC), on female breast cancer survivors in mainland China-A randomized, controlled, theoretically-derived intervention trial. ( 27400910 )
2016
28
Characterization of Korean Male Breast Cancer Using an Online Nationwide Breast-Cancer Database: Matched-Pair Analysis of Patients With Female Breast Cancer. ( 27100414 )
2016
29
Risk of Second Non-Breast Primary Cancer in Male and Female Breast Cancer Patients: A Population-Based Cohort Study. ( 26894298 )
2016
30
Prediction of Female Breast Cancer Incidence among the Aging Society in Kanagawa, Japan. ( 27532126 )
2016
31
Single Female Breast Cancer Patients' Perspectives on Intimate Relationships. ( 27126077 )
2016
32
Geographical Inequalities in Surgical Treatment for Localized Female Breast Cancer, Queensland, Australia 1997-2011: Improvements over Time but Inequalities Remain. ( 27447656 )
2016
33
Female breast cancer burden was increasing during the 40A years in Hebei Province, China: a population-based study. ( 27405613 )
2016
34
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. ( 27064666 )
2016
35
The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. ( 27107051 )
2016
36
PAHs and PM2.5 emissions and female breast cancer incidence in metro Atlanta and rural Georgia. ( 26983363 )
2016
37
Incidence rate of female breast cancer in urban Shijiazhuang in 2012 and modifiable risk factors. ( 27766774 )
2016
38
Interventions to Manage Uncertainty and Fear of Recurrence in Female Breast Cancer Survivors: A Review of the Literature. ( 27857253 )
2016
39
Study on female breast cancer imaging screening consultation network in Guangdong Province, China. ( 27172743 )
2016
40
Role of PALB2 Polymorphisms with Regard to Susceptibility to Female Breast Cancer Risk in the Chinese Population. ( 26981788 )
2016
41
Comparison of Clinicopathological Features and Treatments between Young (a8o40 Years) and Older (>40 Years) Female Breast Cancer Patients in West China: A Retrospective, Epidemiological, Multicenter, Case Only Study. ( 27031236 )
2016
42
Incidence, mortality and survival of female breast cancer during 2003-2011 in Jiangsu province, China. ( 27478317 )
2016
43
Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. ( 26905999 )
2016
44
Identification of novel serum peptides biomarkers for female breast cancer patients in Western China. ( 26705257 )
2016
45
Male Breast Cancer Incidence and Mortality Risk in the Japanese Atomic Bomb Survivors - Differences in Excess Relative and Absolute Risk from Female Breast Cancer. ( 27286002 )
2016
46
Female breast cancer in Central and South America. ( 27678313 )
2016
47
Dietary patterns and the risk of female breast cancer among participants of the Canadian National Enhanced Cancer Surveillance System. ( 27348110 )
2016
48
Relationship between five GWAS-identified single nucleotide polymorphisms and female breast cancer in the Chinese Han population. ( 26803517 )
2016
49
Therapy modalities to reduce lymphoedema in female breast cancer patients: a systematic review and meta-analysis. ( 27460637 )
2016
50
OGG1 Mutations and Risk of Female Breast Cancer: Meta-Analysis and Experimental Data. ( 26089588 )
2015

Variations for Female Breast Cancer

Expression for Female Breast Cancer

Search GEO for disease gene expression data for Female Breast Cancer.

Pathways for Female Breast Cancer

Pathways related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 19)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 ATM BRCA2 ERCC4 ERCC5 PALB2 TP53
2 12.46 AR BRCA2 ERBB2 TP53
3
Show member pathways
12.24 ATM BRCA2 ERCC4 ERCC5 ESR1 TP53
4
Show member pathways
12.22 AR ATM BRCA2 ERBB2 ESR1 PGR
5
Show member pathways
11.97 ATM BRCA2 ERCC4 PALB2
6
Show member pathways
11.94 ATM BRCA2 PALB2
7 11.9 ATM BRCA2 ERCC4 PHB TOP2A TP53
8 11.86 ATM ERCC5 TP53
9 11.77 ATM ERBB2 TP53
10
Show member pathways
11.73 ERBB2 ESR1 PGR
11 11.65 BRCA2 ERCC4 PALB2
12
Show member pathways
11.61 AR ESR1 PGR
13
Show member pathways
11.55 ATM BRCA2 TP53
14 11.42 ATM ERBB2 TOP2A TP53
15 11.4 ATM ERBB2 TP53
16 11.29 AR ATM BRCA2 ESR1 PHB TP53
17
Show member pathways
10.92 ATM TP53
18 10.83 ATM TP53
19 10.62 CYP1A1 ESR1

GO Terms for Female Breast Cancer

Cellular components related to Female Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.77 AR ATM BRCA2 ERBB2 ERCC4 ERCC5
2 protein complex GO:0043234 9.55 AR BRCA2 ESR1 TOP2A TP53
3 nuclear chromosome, telomeric region GO:0000784 9.43 ATM BRCA2 ERCC4
4 nucleoplasm GO:0005654 9.36 AR ATM BRCA2 ERCC4 ERCC5 ESR1

Biological processes related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 28)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 AR ERBB2 PHB TP53
2 cell proliferation GO:0008283 9.88 AR BRCA2 CYP1A1 ERBB2 TP53
3 DNA repair GO:0006281 9.85 ATM BRCA2 ERCC4 ERCC5 PALB2
4 positive regulation of transcription, DNA-templated GO:0045893 9.85 AR BRCA2 ESR1 PHB TOX3 TP53
5 multicellular organism growth GO:0035264 9.72 AR ATM PALB2
6 steroid hormone mediated signaling pathway GO:0043401 9.69 AR ESR1 PGR
7 female gonad development GO:0008585 9.64 ATM BRCA2
8 response to X-ray GO:0010165 9.63 BRCA2 TP53
9 nucleotide-excision repair, DNA incision, 3-to lesion GO:0006295 9.63 ERCC4 ERCC5
10 nucleotide-excision repair, preincision complex stabilization GO:0006293 9.62 ERCC4 ERCC5
11 regulation of apoptotic process GO:0042981 9.62 ATM ESR1 PHB TP53
12 mammary gland alveolus development GO:0060749 9.61 AR ESR1
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.61 BRCA2 TP53
14 resolution of meiotic recombination intermediates GO:0000712 9.6 ERCC4 TOP2A
15 determination of adult lifespan GO:0008340 9.59 ATM TP53
16 UV protection GO:0009650 9.58 ERCC4 ERCC5
17 inner cell mass cell proliferation GO:0001833 9.58 BRCA2 PALB2
18 DNA synthesis involved in DNA repair GO:0000731 9.58 ATM BRCA2 PALB2
19 replicative senescence GO:0090399 9.57 ATM TP53
20 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.56 AR ERBB2
21 negative regulation of telomerase activity GO:0051974 9.54 ERCC4 TP53
22 response to UV-C GO:0010225 9.52 BRCA2 ERCC5
23 progesterone receptor signaling pathway GO:0050847 9.49 PGR PHB
24 double-strand break repair via homologous recombination GO:0000724 9.46 ATM BRCA2 ERCC4 PALB2
25 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.43 AR PGR
26 strand displacement GO:0000732 9.43 ATM BRCA2 PALB2
27 nucleotide-excision repair GO:0006289 9.26 BRCA2 ERCC4 ERCC5 TP53
28 cellular response to DNA damage stimulus GO:0006974 9.17 ATM BRCA2 ERCC4 ERCC5 PALB2 TOP2A

Molecular functions related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.85 AR ESR1 TOP2A TOX3 TP53
2 histone deacetylase binding GO:0042826 9.7 PHB TOP2A TP53
3 single-stranded DNA binding GO:0003697 9.69 BRCA2 ERCC4 ERCC5
4 ATPase binding GO:0051117 9.67 AR ESR1 PGR
5 steroid hormone receptor activity GO:0003707 9.65 AR ESR1 PGR
6 DNA binding GO:0003677 9.65 AR ATM BRCA2 ERCC4 ERCC5 ESR1
7 protein N-terminus binding GO:0047485 9.56 ATM ERCC4 ERCC5 TP53
8 protein C-terminus binding GO:0008022 9.55 BRCA2 ERBB2 ERCC4 PHB TOP2A
9 endodeoxyribonuclease activity GO:0004520 9.54 ERCC4 ERCC5
10 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.54 AR ESR1 PGR
11 steroid binding GO:0005496 9.5 AR ESR1 PGR
12 estrogen response element binding GO:0034056 9.43 ESR1 TOX3
13 enzyme binding GO:0019899 9.17 AR CYP1A1 ESR1 PGR PHB TOP2A
14 protein binding GO:0005515 10.25 AR ATM BRCA2 CYP1A1 ERBB2 ERCC4

Sources for Female Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....